News 2013

ARGX-110 meets translational development goals in Phase Ib cancer study

Date: 17/12/2013

17 December 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study (more…)

arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer

Date: 04/11/2013

4 November 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). (more…)

arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B

Date: 04/11/2013

4 November 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X has raised EUR 5 million ($6.8 million) as an extension of its series B financing round (more…)

DCPrime and Janssen to collaborate on potential new therapy

Date: 03/10/2013

3 October 2013, Leiden, The Netherlands – Cancer vaccine company DCPrime BV today announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals, Inc. (more…)

ArGEN-X initiates clinical Phase IB study of ARGX-111 in cancer

Date: 17/09/2013

17 September 2013, Breda, the Netherlands, and Ghent, Belgium – arGEN-X announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year. (more…)

ArGEN-X identifies potent antibody antagonists against complex chonic pain target Nav1.7

Date: 12/09/2013

12 September 2013, Breda, the Netherlands and Ghent, Belgium – arGEN-X announces it has successfully generated potent antibody antagonists of Nav1.7, using its proprietary SIMPLE Antibody™ technology. (more…)

Okapi Sciences enters into license agreement to develop & commercialise the world’s first antiviral veterinary drug

Date: 02/09/2013

22 August 2013, Leuven, Belgium – Okapi Sciences NV announces today that it has entered into an exclusive agreement with Novartis Animal Health for the joint development and commercialisation of an antiviral treatment for cats. (more…)

Argen-x grants licenses to its NHANCE™ antibody half-life extension technology

Date: 06/08/2013

August 6, 2013, Breda, the Netherlands – arGEN-X today announces the signing of its second non-exclusive license agreement for its antibody half-life extension technology, NHance™. (more…)

NightBalance closes new investment round to enable further growth

Date: 29/07/2013

29 July 2013, Delft – NightBalance today announced that it has closed a new investment round, welcoming new investor Van Herk Investments. (more…)

Cristal Therapeutics raises additional funding

Date: 01/07/2013

1 July 2013, Maastricht and Utrecht – Cristal Therapeutics, the new trade name of the Dutch nanomedicine company Cristal Delivery B.V., (more…)

Cristal Therapeutics appears in BioCentury

Date: 24/06/2013

24 June 2013, Maastricht – In the BioCentury issue of this week (Vol. 21 Issue 25) , Cristal Therapeutics (formerly known as Cristal Delivery) (more…)

DCPrime’s Phase I/IIa trial with dendritic cancer vaccine in AML meets all clinical endpoints

Date: 28/05/2013

28 May 2013, Leiden, the Netherlands – Cancer vaccine company DCPrime today announced the successful completion of its Phase I/IIa study in acute myeloid leukemia (AML). (more…)

Thuja Capital invests in Mellon Medical B.V.

Date: 28/05/2013

28 May 2013, Utrecht, The Netherlands –  Thuja Capital announces today that it has invested in medical technology company Mellon Medical B.V., a newly incorporated company specialized in the development of innovative surgical suturing devices. (more…)

arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

Date: 24/04/2013

Breda, the Netherlands and Ghent, Belgium, April 24, 2013 – arGEN-X announces that it has progressed its second product candidate this year into formal preclinical development. (more…)

Hemics and DEMCON start HandScan development

Date: 22/04/2013

Eindhoven, the Netherlands, April 22, 2013 – Today, Hemics BV and DEMCON Advanced Mechatronics BV announce that they have started developing the HandScan into a commercial product. (more…)

Akeso Medical Imaging renamed Hemics

Date: 08/04/2013

Eindhoven, the Netherlands, April 5, 2013 – Akeso Medical Imaging BV announces today that as of this day the company has adopted a new name: Hemics BV. (more…)

Galapagos to start Phase 2a study with GLPG0974 in IBD patients

Date: 27/03/2013

Mechelen, Belgium; 27 March 2013 – Galapagos NV (Euronext: GLPG) announced today that GLPG0974, (more…)

arGEN-X announces preclinical development of ARGX-112 for dermatology

Date: 25/03/2013

Breda, the Netherlands and Ghent, Belgium March 25, 2013 – arGEN-X, a clinical stage biopharmaceutical company specialized in the discovery and development of highly differentiated human monoclonal antibody therapeutics, (more…)

Enanta Pharmaceuticals Announces Pricing of Initial Public Offering

Date: 21/03/2013

21 March 2013, WATERTOWN, Mass. – Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) today announced the pricing of its initial public offering (more…)

FABPulous announces CE marking of novel rapid acute myocardial infarction triage test

Date: 12/03/2013

12 March 2013, Maastricht, The Netherlands – FABPulous, a diagnostics company specialized in rapid tests in whole blood, announced today the CE marking of its first diagnostic product, the H-FABP True Rapid Test, as an aid in the diagnosis of acute myocardial infarction (AMI). (more…)

arGEN-X expands its therapeutic antibody alliance with Shire

Date: 07/01/2013

January 7, 2013, Breda, the Netherlands, and Ghent, Belgium – arGEN-X is broadening its therapeutic antibody collaboration with Shire. (more…)

arGEN-X initiates Phase Ib study of ARGX-110 in cancer

Date: 07/01/2013

January 7 2013, Breda, the Netherlands, and Ghent, Belgium – arGEN-X announced today the initiation of a Phase Ib first-in-man cancer study with ARGX-110, (more…)